A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Primary Liver Cancer Save

Date Added
November 6th, 2018
PRO Number
Pro00081570
Researcher
Ricardo Yamada

List of Studies

Silhouette
Keywords
Cancer/Gastrointestinal, Liver
Summary

TheraSphere® is a humanitarian use device (HUD) for treating cancer that originates in the liver. TheraSphere® consists of millions of tiny glass beads containing radioactive yttrium-90. The glass radioactive beads (20-30 micrometers in diameter ? about a third of the width of a human hair) are delivered directly to the liver tumors. It can be used to downstage tumors to become eligible for surgery or transplantation. It is also the only medical device approved in the United States to treat primary liver cancer patients with portal vein thrombosis (PVT). TheraSphere® has been approved as an HUD based upon its safety and probable benefit.

Institution
MUSC
Recruitment Contact
Susan Norton
843 814 8874
nortons@musc.edu

Change_preferences

-- OR --

Create_login